Opiant Pharmaceuticals Investor Relations Material

Latest events

Q2 2022

Opiant Pharmaceuticals

Investor Presentation

16 Feb, 2023

Q4 2022

16 Feb, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Opiant Pharmaceuticals Inc

Access all reports
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company's lead product candidate is naloxone nasal spray that is in Phase III clinical trial for the treatment of opioid overdose. It also engages in developing temporary user-based treatment targeting at treating binge eating disorder (BED); as well as nasal treatments for other addictive/compulsive behaviors and disorders.